Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study.

ABSTRACT:

Background

Mepolizumab, the first widely available anti-interleukin 5 biologic, targets eosinophilic inflammation and has been shown in clinical trials to reduce exacerbations, oral corticosteroid dependence, and healthcare utilization in patients with severe asthma. The impact of mepolizumab in a real-world, publicly funded healthcare setting is unknown. The objective of this study was to describe the demographics and clinical characteristics of real-world patients receiving mepolizumab, and to compare asthma-related outcomes and associated asthma-related costs before and during mepolizumab use.

Methods

This retrospective, observational study in Ontario, Canada, included patients initiating mepolizumab between February 2016 and March 2019. Patients were identified using the

SUBMITTER: Chapman KR 

PROVIDER: S-EPMC10838436 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature